Navigating the Funding Landscape to Accelerate Indication-Agnostic Amylin R&D
3:30 pm - Thursday 3rd December 2026
- Gain insight into where investor appetite is building across selective agonists, combination approaches, oral molecules, antibodies and long-acting amylin strategies
- Understand the key financing stages from seed and Series A through clinical development, strategic partnerships and late-stage capital
- Identify the scientific and clinical milestones investors need to see to de-risk amylin programmes and support the next funding round
- Learn how to articulate a differentiated value proposition around receptor strategy, efficacy, tolerability, modality, patient positioning and indication expansion to attract investment and strategic partners
